Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms

Yun Wu, Robert A. Soslow, David S. Marshall, Mario Leitao, Beiyun Chen

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The aim of this study is to examine Her-2/neu gene amplification and protein overexpression in a spectrum of ovarian neoplasms using both immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) techniques that are FDA approved. This study is focused on early stage tumors including both carcinomas and borderline tumors. FDA-approved IHC and FISH for Her-2/neu were performed on formalin-fixed, paraffin-embedded tissue from 79 ovarian neoplasms representing a broad spectrum of tumor types as well as four normal ovaries. All tumors were either stage I or stage II. Tumor and normal tissue were studied collectively using a tissue microarray (TMA). HercepTest (DAKO) and PathVysion Her-2/neu probe kit (Vysis Inc.) were used for IHC and FISH analysis. FISH analysis of serous carcinomas demonstrated Her-2/neu gene amplification in 3 (18%) of 17 cases. Two of three cases showing Her-2/neu gene amplification were scored 1+ using IHC, while the remaining case was scored as 0. Analysis of endometrioid carcinomas demonstrated Her-2/neu amplification using FISH in 1 of 10 (10%) cases. IHC in this case was scored 2+ (positive). None of the remaining 44 tumors, including clear cell carcinoma (n = 12), transitional cell carcinoma (n = 1), mixed epithelial carcinoma (n = 7), carcinoma not otherwise specified (n = 1), and 31 borderline tumors (mucinous, n = 17; endometrioid, n = 7; serous, n = 7), showed Her-2/neu gene amplification or protein overexpression. Normal ovaries were negative as well. Amplification of Her-2/neu in early stage ovarian neoplasms is infrequent, 6.7% overall. Due to the limited number of informative cases, we were unable to determine the clinical significance of Her-2/neu amplification in this study. Her-2/neu amplification was restricted to carcinomas and was not encountered in ovarian borderline tumors.

Original languageEnglish (US)
Pages (from-to)570-575
Number of pages6
JournalGynecologic Oncology
Volume95
Issue number3
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Glandular and Epithelial Neoplasms
erbB-2 Genes
Fluorescence In Situ Hybridization
Gene Amplification
Carcinoma
Neoplasms
Ovarian Neoplasms
Ovary
Endometrioid Carcinoma
Transitional Cell Carcinoma
Paraffin
Formaldehyde
Proteins

Keywords

  • Fluorescence in situ hybridization
  • Her-2/neu
  • Immunohistochemistry

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. / Wu, Yun; Soslow, Robert A.; Marshall, David S.; Leitao, Mario; Chen, Beiyun.

In: Gynecologic Oncology, Vol. 95, No. 3, 12.2004, p. 570-575.

Research output: Contribution to journalArticle

Wu, Yun ; Soslow, Robert A. ; Marshall, David S. ; Leitao, Mario ; Chen, Beiyun. / Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. In: Gynecologic Oncology. 2004 ; Vol. 95, No. 3. pp. 570-575.
@article{b365aae90f5c4b178a15bdb80b4da3e0,
title = "Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms",
abstract = "The aim of this study is to examine Her-2/neu gene amplification and protein overexpression in a spectrum of ovarian neoplasms using both immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) techniques that are FDA approved. This study is focused on early stage tumors including both carcinomas and borderline tumors. FDA-approved IHC and FISH for Her-2/neu were performed on formalin-fixed, paraffin-embedded tissue from 79 ovarian neoplasms representing a broad spectrum of tumor types as well as four normal ovaries. All tumors were either stage I or stage II. Tumor and normal tissue were studied collectively using a tissue microarray (TMA). HercepTest (DAKO) and PathVysion Her-2/neu probe kit (Vysis Inc.) were used for IHC and FISH analysis. FISH analysis of serous carcinomas demonstrated Her-2/neu gene amplification in 3 (18{\%}) of 17 cases. Two of three cases showing Her-2/neu gene amplification were scored 1+ using IHC, while the remaining case was scored as 0. Analysis of endometrioid carcinomas demonstrated Her-2/neu amplification using FISH in 1 of 10 (10{\%}) cases. IHC in this case was scored 2+ (positive). None of the remaining 44 tumors, including clear cell carcinoma (n = 12), transitional cell carcinoma (n = 1), mixed epithelial carcinoma (n = 7), carcinoma not otherwise specified (n = 1), and 31 borderline tumors (mucinous, n = 17; endometrioid, n = 7; serous, n = 7), showed Her-2/neu gene amplification or protein overexpression. Normal ovaries were negative as well. Amplification of Her-2/neu in early stage ovarian neoplasms is infrequent, 6.7{\%} overall. Due to the limited number of informative cases, we were unable to determine the clinical significance of Her-2/neu amplification in this study. Her-2/neu amplification was restricted to carcinomas and was not encountered in ovarian borderline tumors.",
keywords = "Fluorescence in situ hybridization, Her-2/neu, Immunohistochemistry",
author = "Yun Wu and Soslow, {Robert A.} and Marshall, {David S.} and Mario Leitao and Beiyun Chen",
year = "2004",
month = "12",
doi = "10.1016/j.ygyno.2004.08.043",
language = "English (US)",
volume = "95",
pages = "570--575",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms

AU - Wu, Yun

AU - Soslow, Robert A.

AU - Marshall, David S.

AU - Leitao, Mario

AU - Chen, Beiyun

PY - 2004/12

Y1 - 2004/12

N2 - The aim of this study is to examine Her-2/neu gene amplification and protein overexpression in a spectrum of ovarian neoplasms using both immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) techniques that are FDA approved. This study is focused on early stage tumors including both carcinomas and borderline tumors. FDA-approved IHC and FISH for Her-2/neu were performed on formalin-fixed, paraffin-embedded tissue from 79 ovarian neoplasms representing a broad spectrum of tumor types as well as four normal ovaries. All tumors were either stage I or stage II. Tumor and normal tissue were studied collectively using a tissue microarray (TMA). HercepTest (DAKO) and PathVysion Her-2/neu probe kit (Vysis Inc.) were used for IHC and FISH analysis. FISH analysis of serous carcinomas demonstrated Her-2/neu gene amplification in 3 (18%) of 17 cases. Two of three cases showing Her-2/neu gene amplification were scored 1+ using IHC, while the remaining case was scored as 0. Analysis of endometrioid carcinomas demonstrated Her-2/neu amplification using FISH in 1 of 10 (10%) cases. IHC in this case was scored 2+ (positive). None of the remaining 44 tumors, including clear cell carcinoma (n = 12), transitional cell carcinoma (n = 1), mixed epithelial carcinoma (n = 7), carcinoma not otherwise specified (n = 1), and 31 borderline tumors (mucinous, n = 17; endometrioid, n = 7; serous, n = 7), showed Her-2/neu gene amplification or protein overexpression. Normal ovaries were negative as well. Amplification of Her-2/neu in early stage ovarian neoplasms is infrequent, 6.7% overall. Due to the limited number of informative cases, we were unable to determine the clinical significance of Her-2/neu amplification in this study. Her-2/neu amplification was restricted to carcinomas and was not encountered in ovarian borderline tumors.

AB - The aim of this study is to examine Her-2/neu gene amplification and protein overexpression in a spectrum of ovarian neoplasms using both immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) techniques that are FDA approved. This study is focused on early stage tumors including both carcinomas and borderline tumors. FDA-approved IHC and FISH for Her-2/neu were performed on formalin-fixed, paraffin-embedded tissue from 79 ovarian neoplasms representing a broad spectrum of tumor types as well as four normal ovaries. All tumors were either stage I or stage II. Tumor and normal tissue were studied collectively using a tissue microarray (TMA). HercepTest (DAKO) and PathVysion Her-2/neu probe kit (Vysis Inc.) were used for IHC and FISH analysis. FISH analysis of serous carcinomas demonstrated Her-2/neu gene amplification in 3 (18%) of 17 cases. Two of three cases showing Her-2/neu gene amplification were scored 1+ using IHC, while the remaining case was scored as 0. Analysis of endometrioid carcinomas demonstrated Her-2/neu amplification using FISH in 1 of 10 (10%) cases. IHC in this case was scored 2+ (positive). None of the remaining 44 tumors, including clear cell carcinoma (n = 12), transitional cell carcinoma (n = 1), mixed epithelial carcinoma (n = 7), carcinoma not otherwise specified (n = 1), and 31 borderline tumors (mucinous, n = 17; endometrioid, n = 7; serous, n = 7), showed Her-2/neu gene amplification or protein overexpression. Normal ovaries were negative as well. Amplification of Her-2/neu in early stage ovarian neoplasms is infrequent, 6.7% overall. Due to the limited number of informative cases, we were unable to determine the clinical significance of Her-2/neu amplification in this study. Her-2/neu amplification was restricted to carcinomas and was not encountered in ovarian borderline tumors.

KW - Fluorescence in situ hybridization

KW - Her-2/neu

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=9944239917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9944239917&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.08.043

DO - 10.1016/j.ygyno.2004.08.043

M3 - Article

VL - 95

SP - 570

EP - 575

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -